CSM Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$33M Sell
27,478
-1,610
-6% -$1.64M 0.7% 32
2026
Q1
$26.8M Buy
29,088
+15,949
+121% +$16.2M 0.66% 36
2025
Q4
$14.1M Buy
13,139
+2,165
+20% +$2.07M 0.38% 74
2025
Q3
$8.37M Buy
10,974
+9,897
+919% +$7.36M 0.23% 97
2025
Q2
$839K Buy
1,077
+37
+4% +$28.8K 0.02% 309
2025
Q1
$859K Sell
1,040
-5
-0.5% -$4.16K 0.05% 99
2024
Q4
$807K Buy
1,045
+245
+31% +$203K 0.04% 99
2024
Q3
$708K Sell
800
-422
-35% -$379K 0.05% 105
2024
Q2
$1.11M Sell
1,222
-140
-10% -$112K 0.08% 97
2024
Q1
$1.06M Sell
1,362
-200
-13% -$142K 0.07% 104
2023
Q4
$909K Hold
1,562
0.07% 111
2023
Q3
$838K Sell
1,562
-850
-35% -$438K 0.07% 104
2023
Q2
$1.13M Sell
2,412
-1,050
-30% -$440K 0.09% 106
2023
Q1
$1.19M Hold
3,462
0.1% 95
2022
Q4
$1.27M Buy
3,462
+50
+1% +$17.7K 0.12% 91
2022
Q3
$1.1M Sell
3,412
-510
-13% -$162K 0.12% 95
2022
Q2
$1.27M Sell
3,922
-650
-14% -$195K 0.12% 83
2022
Q1
$1.31M Sell
4,572
-25
-0.5% -$6.43K 0.09% 92
2021
Q4
$1.27M Buy
4,597
+90
+2% +$22.8K 0.08% 100
2021
Q3
$1.04M Hold
4,507
0.08% 101
2021
Q2
$1.03M Buy
+4,507
New +$905K 0.07% 101

Other funds holding LLY

CSM Advisors's LLY Position: Q2 2026 in Review

CSM Advisors reduced its Eli Lilly (LLY) stake by 5.5% in Q2 2026, selling an estimated $1.64M and leaving 27,478 shares worth $33M. The position accounts for 0.7% of the portfolio, ranked #32.

CSM Advisors first reported a position in LLY in Q2 2021 and has held it in 21 quarters since. 4,599 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • CSM Advisors held 27,478 shares of Eli Lilly worth $33M as of Q2 2026.
  • CSM Advisors sold 1,610 Eli Lilly shares in Q2 2026, an estimated $1.64M.
  • Eli Lilly made up 0.7% of CSM Advisors's portfolio in Q2 2026, its #32 holding.
  • CSM Advisors first reported a position in Eli Lilly in Q2 2021 and has held it in 21 quarters since.
  • 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on CSM Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.